Biostax Corp Begins Transition to Private Operations Biostax Corp has initiated its voluntary delisting from the OTC Pink Market, filing the necessary paperwork with the SEC today. This move, supported by 76.4% of shareholders, aims to reduce costs and focus on advancing its drug pipeline, including treatments for autoimmune hepatitis and HIV.1